Kimelman & Baird, LLC Nektar Therapeutics Transaction History
Kimelman & Baird, LLC
- $1.21 Trillion
- Q2 2024
A detailed history of Kimelman & Baird, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Kimelman & Baird, LLC holds 200 shares of NKTR stock, worth $252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200Holding current value
$252% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NKTR
# of Institutions
140Shares Held
135MCall Options Held
32.8KPut Options Held
55.5K-
Deep Track Capital, LP Greenwich, CT17.9MShares$22.5 Million0.73% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$19.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$16.3 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.46MShares$11.9 Million0.21% of portfolio
-
Eventide Asset Management, LLC Boston, MA7.53MShares$9.49 Million0.16% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $236M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...